Merck bets $334m on Korea as Asia-Pacific biopharma hub
German science and technology company Merck has opened a $334 million bioprocessing plant in Daejeon, its largest life science investment in Asia-Pacific, as it seeks to bring production closer to regional drugmakers. The company said Thursday that the 44,500-square-meter facility in Dungok, Daejeon

German science and technology company Merck has opened a $334 million bioprocessing plant in Daejeon, its largest life science investment in Asia-Pacific, as it seeks to bring production closer to regional drugmakers. The company said Thursday that the 44,500-square-meter facility in Dungok, Daejeon
💬 留言板 — 歡迎分享你的想法!
登入 Google 帳號即可留言